KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Depreciation Expense (2022 - 2026)

Pacific Biosciences Of California has reported Depreciation Expense over the past 4 years, most recently at $2.7 million for Q4 2025.

  • For Q4 2025, Depreciation Expense fell 3.27% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $13.0 million, down 5.62%, while the annual FY2025 figure was $13.0 million, 5.62% down from the prior year.
  • Depreciation Expense for Q4 2025 was $2.7 million at Pacific Biosciences Of California, up from $2.5 million in the prior quarter.
  • Over five years, Depreciation Expense peaked at $5.1 million in Q1 2025 and troughed at $2.3 million in Q1 2022.
  • A 4-year average of $3.0 million and a median of $2.8 million in 2023 define the central range for Depreciation Expense.
  • On a YoY basis, Depreciation Expense climbed as much as 58.36% in 2025 and fell as far as 41.31% in 2025.
  • Year by year, Depreciation Expense stood at $2.5 million in 2022, then increased by 18.48% to $3.0 million in 2023, then fell by 5.68% to $2.8 million in 2024, then fell by 3.27% to $2.7 million in 2025.
  • Business Quant data shows Depreciation Expense for PACB at $2.7 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.